Clinical Data S-3 of Common Stock Declared Effective by SEC.

Business Editors/Health/Medical Writers

NEWTON, Mass.--(BUSINESS WIRE)--Jan. 13, 2004

Clinical Data, Inc. (NASDAQ:CLDA) announced today that the Securities and Exchange Commission has declared effective as of January 12, 2004, the company's Form S-3 shelf registration statement (SEC File No. 333-111347) covering 2,672,500 shares of its common stock. Other than 200,000 of the shares registered on behalf of an officer and director of the company, the remaining 2,427,250 shares are newly issued as a result of the conversion of 247,250 shares of the company's Series A Nonvoting Convertible Preferred Stock that was issued in connection with Clinical Data's acquisition of Group Practice Services, Inc. and Landmark Scientific, Inc.

The shares registered may be sold to the public from time to time or at any time. However, of the shares registered, 2,408,780 shares are held by officers and directors of the company and their affiliates, and will be subject to additional applicable restrictions on resale. In addition, the holders of these shares, which represent over 90% of the shares covered by the registration statement, have informed the company that they have no present intention to sell any of such shares. Clinical Data will not receive any proceeds from the sale of any of the shares sold under the registration statement.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of any securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state. The registration statement and all other SEC filings by the company are available for review at http://www.sec.gov/. Copies of the final prospectus included in the registration statement may be obtained from Investor Relations, Clinical Data, Inc. 2 Thurber Boulevard, Smithfield, Rhode Island 02917.

About Clinical Data

Clinical Data, Inc., through its domestic and foreign subsidiaries, focuses on the needs of physician offices and smaller clinical laboratories. The Company provides a complete range of products and consulting services to the growing physician office laboratory market and offers blood chemistry instrumentation and diagnostic assays to clinics and small hospitals worldwide.

Except for any historical information contained in this press release, the matters discussed herein include forward looking statements within the meaning of the Securities Act of 1933, as amended, and the Securities Exchange Act of 1934, as amended, that involve risks and uncertainties. Actual results could differ materially from those expressed in such statements and readers are referred to the Company's SEC reports and filings.